Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
Launched by ABBOTT · Jun 18, 2006
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject was age 20 or older and in good health (Investigator discretion) with a recent stable medical history.
- • Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
- Exclusion Criteria:
- • Subject had previously received anti-TNF therapy.
- • Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVA, UVB or PUVA phototherapy
- • Subject is taking or requires oral or injectable corticosteroids
- • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
- • Female subject who is pregnant or breast-feeding or considering becoming pregnant
About Abbott
Abbott is a global healthcare company dedicated to improving lives through innovative medical technologies, diagnostics, nutrition, and branded generic pharmaceuticals. With a commitment to advancing health and wellness, Abbott conducts clinical trials to evaluate the safety and efficacy of its diverse portfolio of products, which span multiple therapeutic areas, including cardiovascular, diabetes care, and neurology. The company employs rigorous research methodologies and collaborates with healthcare professionals and institutions worldwide to ensure the highest standards of clinical integrity and patient safety. Abbott's mission is to deliver impactful solutions that enhance patient outcomes and contribute to the advancement of global healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hokkaido, , Japan
Chubu, , Japan
Chugoku, , Japan
Kanto, , Japan
Kinki, , Japan
Kyusyu, , Japan
Shikoku, , Japan
Tohoku, , Japan
Patients applied
Trial Officials
Noritaka Inomata, Ph.D.
Study Director
Abbott Japan Co.,Ltd
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials